The direct costs of epilepsy in Russia. A prospective cost-of-illness study from a single center in Moscow

Alla Guekht, Maria Mizinova, Igor Kaimovsky, Oksana Danilenko, Elisa Bianchi, Ettore Beghi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective The objective of this study was to investigate prospectively the direct costs of epilepsy in Russia, taking a patient perspective and a bottom-up approach. Methods The study was conducted in adolescents and adults with epilepsy seen in the ambulatory services of a city hospital in Moscow. Patients were assigned to different prognostic categories: newly diagnosed epilepsy; epilepsy in remission for 2 + years; epilepsy in remission for < 2 years or with occasional seizures; active, nondrug-resistant epilepsy; drug-resistant epilepsy; and drug-resistant epilepsy in surgical candidates. Patients were followed prospectively for 12 months. Demographic and clinical features at admission were collected and correlated with costs. Cost estimates were based on the Russian National Health Service perspective and its implementation in Moscow. Cost items included drugs and laboratory/instrumental tests. The costs per patient were calculated for the entire sample and for each prognostic category separately. Univariate and multivariate analyses were performed. Results Included were 738 patients (393 men, 345 women aged 14–85 years). The median annual cost/patient was €955 (IQR 521–2134; range 51–10,904). The median cost of drugs was €643 (IQR 288–1866; range 0–9960), and the median cost of laboratory/instrumental testing was €202 (IQR 160–270; range 20–1217). Mean costs varied across prognostic categories ranging from €782 in newly diagnosed patients to €3777 in patients with drug-resistant epilepsy. Mean (SD) hospital costs ranged from €646.7 (109.0) in patients with occasional seizures to €950.0 (28.3) in surgical candidates. Independent predictors of total costs were younger age at diagnosis, disability status, generalized seizures, multiple seizure types, seizure severity, and etiology. Significance The cost of epilepsy in Moscow varies significantly depending on disease characteristics and response to drug treatment.

Original languageEnglish
Pages (from-to)122-126
Number of pages5
JournalEpilepsy and Behavior
Volume64
DOIs
Publication statusPublished - Nov 1 2016

Fingerprint

Moscow
Cost of Illness
Russia
Epilepsy
Costs and Cost Analysis
Seizures
Drug Costs
Hospital Costs
Urban Hospitals
National Health Programs
Pharmaceutical Preparations
Multivariate Analysis
Demography

Keywords

  • Diagnostic tests
  • Direct costs
  • Drugs
  • Epilepsy
  • Russia

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Behavioral Neuroscience

Cite this

The direct costs of epilepsy in Russia. A prospective cost-of-illness study from a single center in Moscow. / Guekht, Alla; Mizinova, Maria; Kaimovsky, Igor; Danilenko, Oksana; Bianchi, Elisa; Beghi, Ettore.

In: Epilepsy and Behavior, Vol. 64, 01.11.2016, p. 122-126.

Research output: Contribution to journalArticle

Guekht, Alla ; Mizinova, Maria ; Kaimovsky, Igor ; Danilenko, Oksana ; Bianchi, Elisa ; Beghi, Ettore. / The direct costs of epilepsy in Russia. A prospective cost-of-illness study from a single center in Moscow. In: Epilepsy and Behavior. 2016 ; Vol. 64. pp. 122-126.
@article{f778f901aee7403d89419ea1c901abe5,
title = "The direct costs of epilepsy in Russia. A prospective cost-of-illness study from a single center in Moscow",
abstract = "Objective The objective of this study was to investigate prospectively the direct costs of epilepsy in Russia, taking a patient perspective and a bottom-up approach. Methods The study was conducted in adolescents and adults with epilepsy seen in the ambulatory services of a city hospital in Moscow. Patients were assigned to different prognostic categories: newly diagnosed epilepsy; epilepsy in remission for 2 + years; epilepsy in remission for < 2 years or with occasional seizures; active, nondrug-resistant epilepsy; drug-resistant epilepsy; and drug-resistant epilepsy in surgical candidates. Patients were followed prospectively for 12 months. Demographic and clinical features at admission were collected and correlated with costs. Cost estimates were based on the Russian National Health Service perspective and its implementation in Moscow. Cost items included drugs and laboratory/instrumental tests. The costs per patient were calculated for the entire sample and for each prognostic category separately. Univariate and multivariate analyses were performed. Results Included were 738 patients (393 men, 345 women aged 14–85 years). The median annual cost/patient was €955 (IQR 521–2134; range 51–10,904). The median cost of drugs was €643 (IQR 288–1866; range 0–9960), and the median cost of laboratory/instrumental testing was €202 (IQR 160–270; range 20–1217). Mean costs varied across prognostic categories ranging from €782 in newly diagnosed patients to €3777 in patients with drug-resistant epilepsy. Mean (SD) hospital costs ranged from €646.7 (109.0) in patients with occasional seizures to €950.0 (28.3) in surgical candidates. Independent predictors of total costs were younger age at diagnosis, disability status, generalized seizures, multiple seizure types, seizure severity, and etiology. Significance The cost of epilepsy in Moscow varies significantly depending on disease characteristics and response to drug treatment.",
keywords = "Diagnostic tests, Direct costs, Drugs, Epilepsy, Russia",
author = "Alla Guekht and Maria Mizinova and Igor Kaimovsky and Oksana Danilenko and Elisa Bianchi and Ettore Beghi",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.yebeh.2016.08.031",
language = "English",
volume = "64",
pages = "122--126",
journal = "Epilepsy and Behavior",
issn = "1525-5050",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - The direct costs of epilepsy in Russia. A prospective cost-of-illness study from a single center in Moscow

AU - Guekht, Alla

AU - Mizinova, Maria

AU - Kaimovsky, Igor

AU - Danilenko, Oksana

AU - Bianchi, Elisa

AU - Beghi, Ettore

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Objective The objective of this study was to investigate prospectively the direct costs of epilepsy in Russia, taking a patient perspective and a bottom-up approach. Methods The study was conducted in adolescents and adults with epilepsy seen in the ambulatory services of a city hospital in Moscow. Patients were assigned to different prognostic categories: newly diagnosed epilepsy; epilepsy in remission for 2 + years; epilepsy in remission for < 2 years or with occasional seizures; active, nondrug-resistant epilepsy; drug-resistant epilepsy; and drug-resistant epilepsy in surgical candidates. Patients were followed prospectively for 12 months. Demographic and clinical features at admission were collected and correlated with costs. Cost estimates were based on the Russian National Health Service perspective and its implementation in Moscow. Cost items included drugs and laboratory/instrumental tests. The costs per patient were calculated for the entire sample and for each prognostic category separately. Univariate and multivariate analyses were performed. Results Included were 738 patients (393 men, 345 women aged 14–85 years). The median annual cost/patient was €955 (IQR 521–2134; range 51–10,904). The median cost of drugs was €643 (IQR 288–1866; range 0–9960), and the median cost of laboratory/instrumental testing was €202 (IQR 160–270; range 20–1217). Mean costs varied across prognostic categories ranging from €782 in newly diagnosed patients to €3777 in patients with drug-resistant epilepsy. Mean (SD) hospital costs ranged from €646.7 (109.0) in patients with occasional seizures to €950.0 (28.3) in surgical candidates. Independent predictors of total costs were younger age at diagnosis, disability status, generalized seizures, multiple seizure types, seizure severity, and etiology. Significance The cost of epilepsy in Moscow varies significantly depending on disease characteristics and response to drug treatment.

AB - Objective The objective of this study was to investigate prospectively the direct costs of epilepsy in Russia, taking a patient perspective and a bottom-up approach. Methods The study was conducted in adolescents and adults with epilepsy seen in the ambulatory services of a city hospital in Moscow. Patients were assigned to different prognostic categories: newly diagnosed epilepsy; epilepsy in remission for 2 + years; epilepsy in remission for < 2 years or with occasional seizures; active, nondrug-resistant epilepsy; drug-resistant epilepsy; and drug-resistant epilepsy in surgical candidates. Patients were followed prospectively for 12 months. Demographic and clinical features at admission were collected and correlated with costs. Cost estimates were based on the Russian National Health Service perspective and its implementation in Moscow. Cost items included drugs and laboratory/instrumental tests. The costs per patient were calculated for the entire sample and for each prognostic category separately. Univariate and multivariate analyses were performed. Results Included were 738 patients (393 men, 345 women aged 14–85 years). The median annual cost/patient was €955 (IQR 521–2134; range 51–10,904). The median cost of drugs was €643 (IQR 288–1866; range 0–9960), and the median cost of laboratory/instrumental testing was €202 (IQR 160–270; range 20–1217). Mean costs varied across prognostic categories ranging from €782 in newly diagnosed patients to €3777 in patients with drug-resistant epilepsy. Mean (SD) hospital costs ranged from €646.7 (109.0) in patients with occasional seizures to €950.0 (28.3) in surgical candidates. Independent predictors of total costs were younger age at diagnosis, disability status, generalized seizures, multiple seizure types, seizure severity, and etiology. Significance The cost of epilepsy in Moscow varies significantly depending on disease characteristics and response to drug treatment.

KW - Diagnostic tests

KW - Direct costs

KW - Drugs

KW - Epilepsy

KW - Russia

UR - http://www.scopus.com/inward/record.url?scp=84991442193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991442193&partnerID=8YFLogxK

U2 - 10.1016/j.yebeh.2016.08.031

DO - 10.1016/j.yebeh.2016.08.031

M3 - Article

VL - 64

SP - 122

EP - 126

JO - Epilepsy and Behavior

JF - Epilepsy and Behavior

SN - 1525-5050

ER -